Evidence map›Paper›PMID 32661867›Full record

ReviewStem cell reviews and reports2021

Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19.

Pinky, Suchi Gupta, Vishnu Krishnakumar, Yashvi Sharma, Amit Kumar Dinda, Sujata Mohanty

Abstract readReview
In one paragraph

Review in Stem cell reviews and reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Therapeutic Applications of Stem Cell-Derived Exosomes.International journal of molecular sciences · 2024
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pinky *Stem Cell Facility (DBT-Centre of Excellence for Stem Cell Research), 1st Floor, ORBO Complex, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.ORCID 0000-0002-8222-4299
Suchi Gupta *Stem Cell Facility (DBT-Centre of Excellence for Stem Cell Research), 1st Floor, ORBO Complex, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.ORCID 0000-0002-6525-8147
Vishnu KrishnakumarStem Cell Facility (DBT-Centre of Excellence for Stem Cell Research), 1st Floor, ORBO Complex, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.ORCID 0000-0002-2410-1717
Yashvi SharmaStem Cell Facility (DBT-Centre of Excellence for Stem Cell Research), 1st Floor, ORBO Complex, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.ORCID 0000-0002-5264-6028
Amit Kumar DindaDepartment of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Sujata MohantyStem Cell Facility (DBT-Centre of Excellence for Stem Cell Research), 1st Floor, ORBO Complex, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. drmohantysujata@gmail.com.ORCID 0000-0002-0047-4914

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent pandemic situation transpired due to coronavirus novel strain SARS-CoV-2 has become a global concern. This human coronavirus (HCov-19) has put the world on high alert as the numbers of confirmed cases are continuously increasing. The world is now fighting against this deadly virus and is leaving no stone unturned to find effective treatments through testing of various available drugs, including those effective against flu, malaria, etc. With an urgent need for the development of potential strategies, two recent studies from China using Mesenchymal Stem Cells (MSCs) to treat COVID-19 pneumonia have shed some light on a potential cure for the COVID-19 infected patients. However, MSCs, despite being used in various other clinical trials have always been questioned for their tendency to aggregate or form clumps in the injured or disease microenvironment. It has also been reported in various studies that exosomes secreted by these MSCs, contribute towards the cell's biological and therapeutic efficacy. There have been reports evaluating the safety and feasibility of these exosomes in various lung diseases, thereby proposing them as a cell-free therapeutic agent. Also, attractive features like cell targeting, low-immunogenicity, safety, and high biocompatibility distinguish these exosomes from other synthetic nano-vesicles and thus potentiate their role as a drug delivery nano-platform. Building upon these observations, herein, efforts are made to give an overview of stem cell-derived exosomes as an appealing therapeutic agent and drug delivery nano-carrier. In this review, we briefly recapitulate the recent evidence and developments in understanding exosomes as a promising candidate for novel nano-intervention in the current pandemic scenario. Furthermore, this review will highlight and discuss mechanistic role of exosomes to combat severe lung pathological conditions. We have also attempted to dwell into the nano-formulation of exosomes for its better applicability, storage, and stability thereby conferring them as off the shelf therapeutic.

Indexed as

COVID-19CytokinesExosomesHumansMesenchymal Stem CellsMesenchymal Stem Cell TransplantationPandemicsSARS-CoV-2CytokinesDrug deliveryImmuno-modulationLung diseasesNano-formulationTherapeutics

Identifiers

PMID32661867
PMCPMC7357441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.